09.07.2012 - Spanish molecular diagnostics company Inbiomotion S.L. has raised €2m in a series A round.
The new investor, Ysios Capital, led the round. Fundacio Vila Casas and JVRisk Technologies also participated. Inbiomotion is a 2010 spin-off from the Institute for Research in Biomedicine (IRB Barcelona) and the Catalan Institution for Research and Advanced Studies (ICREA). The firm develops biomarkers to predict bone metastasis from primary tumour biopsies, with its lead biomarker coding for an undisclosed nuclear protein. Inbiomotion, based in the Barcelona Science Park and founded by Roger Gomis, is carrying out a trial to validate the capacity of its marker to predict future bone metastasis using technology developed by IRB Barcelona. The investment raised will go to fund the validation of this marker through various clinical trials in Barcelona and England, and to advance development through regulatory approval. According to Inbiomotion, its biomarker has been validated with more than 900 patient samples in two different trials carried out with independent techniques (gene expression and immunohistochemistry), with a negative predictive value of 95%.
29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more